NephrologyVertex
Vertex Pharmaceuticals Reports Phase 3 Results for Inaxaplin in APOL1-Mediated Kidney Disease
BMI
Biotechnology Media Insights
Editorial Team · February 8, 2024
Vertex announces Phase 3 trial results showing inaxaplin significantly reduces proteinuria and slows kidney function decline in APOL1-mediated kidney disease.
Vertex Pharmaceuticals today announced Phase 3 trial results for inaxaplin in patients with APOL1-mediated kidney disease. The trial met its primary endpoint, demonstrating a significant reduction in proteinuria and slowing of kidney function decline compared to placebo. These results support regulatory submissions for inaxaplin in APOL1-mediated kidney disease.
BMI
Biotechnology Media Insights
Published by Biotechnology Media Insights — your trusted source for pharmaceutical, biotech, and life sciences news.